19 diciembre 2019
PharmaMar y Jazz Pharmaceuticals Firman un Acuerdo de Licencia en Exclusiva para ZEPSYRE en EE.UU. Jazz hará un pago inicial de 200 millones de dólares a PharmaMar. PharmaMar también podrá recibir hasta 800 millones de dólares en potenciales pagos por hitos, además de los royalties sobre las ventas netas. Teleconferencia el 9 de Enero 2020 .
Small Cell Lung Cancer . Tras Decadas de No salir Ningún Tratamiento al Mercado al No Triunfar Ningún Fármaco en la I+D ... What´s New In SCLC ? .
Podio en Primera , Segunda y Tercera Línea en Tratamientos de Small Cell Lung Cancer .
Para Primera Línea se Aprobó en 2019 y por tanto Medalla de Platino para :
*.- TECENTRIQ ( Atezolizumab de Roche / Genentech ) .
También para Primera línea podría Aprobarse en marzo 2020 y por tanto Medalla de Oro para :
*.- IMFINZI ( Durvalumab de Astra Zeneca ) .
**********************************
Para Segunda Línea podría Aprobarse en 2020 y por tanto la Medalla de Bronce sería para :
*.- Zepsyre ( Lurbinectedin de PharmaMar ) .
*********************************
Tercera Línea tenemos Dos Fármacos Aprobados Ya y por tanto Comparten Medalla de Cobre :
*.- OPDIVO . Aprobado en 2018 ( Nivolumab de Bristol ) .
*.- KEYTRUDA . Aprobado en 2019 ( Pembrolizumab de Merck ) .
*********************************
Yondelis® . Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas . Una Combinación que Podría actuar en Favor del Yondelis para que consiga Mejores Respuestas Clínicas .
Published December 2019 .
Roberta Frapolli, Ezia Bello, Marianna Ponzo, Ilaria Craparotta, Laura Mannarino, Sara Ballabio, Sergio Marchini, Laura Carrassa, Paolo Ubezio, Luca Porcu, Silvia Brich, Roberta Sanfilippo, Paolo Giovanni Casali, Alessandro Gronchi, Silvana Pilotti and Maurizio D'Incalci
Abstract
This study was aimed at investigating whether the PPARγ agonist pioglitazone—given in combination with trabectedin—is able to reactivate adipocytic differentiation in myxoid liposarcoma (MLS) patient-derived xenografts, overcoming resistance to trabectedin.
Experimental Design:
The antitumor and biological effects of trabectedin, pioglitazone, and the combination of the two drugs were investigated in nude mice bearing well-characterized MLS xenografts representative of innate or acquired resistance against trabectedin. Pioglitazone and trabectedin were given by daily oral and weekly i.v. administrations, respectively. Molecular studies were performed by using microarrays approach, real-time PCR, and Western blotting.
We found that the resistance of MLS against trabectedin is associated with the lack of activation of adipogenesis. The PPARγ agonist pioglitazone reactivated adipogenesis, assessed by histologic and gene pathway analyses. Pioglitazone was well tolerated and did not increase the toxicity of trabectedin. The ability of pioglitazone to reactivate adipocytic differentiation was observed by morphologic examination, and it is consistent with the increased expression of genes such as ADIPOQ implicated in the adipogenesis process. The determination of adiponectin by Western blotting constitutes a good and reliable biomarker related to MLS adipocytic differentiation.
Conclusions:
The finding that the combination of pioglitazone and trabectedin induces terminal adipocytic differentiation of some MLSs with the complete pathologic response and cure of tumor-bearing mice provides a strong rationale to test the combination of trabectedin and pioglitazone in patients with MLS.
©2019 American Association for Cancer Research
绿叶制药希望通过与PharmaMar的合作进一步拓展自身在肿瘤领域的研发产品线，也希望通过该创新药为广大中国医生和患者提供新的治疗选择。
绿叶制药合作创新药Lurbinectedin(Zepsyre?)在美国申报NDA
- 2019-12-18 21:40:52格隆汇
Suscribirse a:
Entradas (Atom)